| Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study K Squires, C Kityo, S Hodder, M Johnson, E Voronin, D Hagins, ... The lancet HIV 3 (9), e410-e420, 2016 | 100 | 2016 |
| Brief report: switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected adults with renal impairment: 96-week results … FA Post, P Tebas, A Clarke, L Cotte, WR Short, ME Abram, S Jiang, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 74 (2), 180-184, 2017 | 63 | 2017 |
| Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label … JJ Eron, JD Lelievre, R Kalayjian, J Slim, AK Wurapa, JL Stephens, ... The Lancet HIV 6 (1), e15-e24, 2019 | 42 | 2019 |
| Brief report: efficacy and safety of switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) in virologically suppressed women S Hodder, K Squires, C Kityo, D Hagins, A Avihingsanon, A Kido, S Jiang, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 78 (2), 209-213, 2018 | 20 | 2018 |
| HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens GD Huhn, M Ramgopal, MK Jain, F Hinestrosa, DM Asmuth, J Slim, ... PloS one 15 (1), e0224875, 2020 | 9 | 2020 |
| Longer-term safety of tenofovir alafenamide in renal impairment F Post, A Clarke, W Short, C Robinson, M Abram, S Jiang, A Cheng, ... HIV MEDICINE 17, 15-15, 2016 | 6 | 2016 |
| Abstract PD8-05: Overall survival (OS) results from the phase III PHENIX trial of HER2+ metastatic breast cancer treated with pyrotinib plus capecitabine Z Jiang, M Yan, L Bian, T Wang, X Hu, Q Zhang, Q Ouyang, J Feng, Y Yin, ... Cancer Research 82 (4_Supplement), PD8-05-PD8-05, 2022 | 4 | 2022 |
| Lag selection in stochastic additive models S Jiang, L Xue Journal of Nonparametric Statistics 25 (1), 129-146, 2013 | 3 | 2013 |
| P075 Efficacy and safety of switching to EVG/COBI/FTC/TAF in virologically suppressed women S Hodder, K Squires, C Kityo, A Avihingsanon, Y Plotnikova, S Jiang, ... Sexually Transmitted Infections 93 (Suppl 1), A41-A41, 2017 | 2 | 2017 |
| Safety and efficacy of E/C/F/TAF in HIV‐infected adults on chronic hemodialysis JE Eron, JD Lelievre, R Kalayjian | 2 | |
| Safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in HIV-infected adults on chronic haemodialysis J Eron, R Kalayjian, A Wurapa, J Stephens, C McDonald, A Wilkin, ... HIV MEDICINE 19, S16-S16, 2018 | 1 | 2018 |
| Variable selection in semi-parametric models S Jiang | 1 | 2013 |
| Overall survival (OS) results from the phase III PHENIX trial of HER2+ metastatic breast cancer treated with pyrotinib plus capecitabine Z Jiang, M Yan, L Bian, T Wang, X Hu, Q Zhang, Q Ouyang, J Feng, Y Yin, ... Cancer Research 82 (4), 2022 | | 2022 |
| HIV-1/HCV Coinfection Treatment with Single-Tablet Antiviral Regimens (CoSTARs): 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) after Randomized Switch to Elvitegravir/Cobicistat … M Ramgopal, MK Jain, F Hinestrosa, D Asmuth, G Huhn, J Slim, ... HEPATOLOGY 66 (6), 1262A-1263A, 2017 | | 2017 |
| Globally consistent model selection in semi-parametric additive coefficient models S Jiang, L Xue Journal of Nonparametric Statistics 27 (4), 532-551, 2015 | | 2015 |
| lag selection in stochastic additive models Journal of Nonparametric Statistics 25 (1), 129-146 (18), 2013 | | 2013 |
| Efficacy and Safety of Switching to E/C/F/TAF in Virologically Suppressed Women S Hodder, K Squires, C Kityo, D Hagins, A Avihingsanon, Y Plotnikova, ... | | |
